Ursodiol in the long-term treatment of chronic hepatitis: a double-blind multicenter clinical trial.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Journal of Hepatology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0168-8278(05)80558-6PMID 8151107
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts. In vivo studies in the rat.

  1991cited by this paper
• Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: A dose‐response study

  1991cited by this paper
• A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group.

  1991cited by this paper
• Acute effects of ursodeoxycholic and chenodeoxycholic acid on the small intestinal absorption of bile acids.

  1990cited by this paper
• Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of endogenous bile acids in man

  1990cited by this paper
• Ursodeoxycholic acid for the treatment of primary biliary cirrhosis: Interim analysis of a double-blind multicentre randomized trial

  1990cited by this paper
• Ursodeoxycholic acid for primary sclerosing cholangitis.

  1990cited by this paper
• Effects of ursodeoxycholic acid and taurine on serum liver enzymes and bile acids in chronic hepatitis.

  1990cited by this paper
• Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes

  1990cited by this paper
• Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration

  1990cited by this paper
• Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Interim analysis of a double-blind multicentre randomized trial. The UDCA-PBC Study Group.

  1990cited by this paper
• Prognosis in primary biliary cirrhosis: Model for decision making

  1989cited by this paper
• Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial.

  1989cited by this paper
• Effect of ursodeoxycholic acid treatment on alanine aminotransferase and gamma-glutamyltranspeptidase serum levels in patients with hypertransaminasemia. Results from a double-blind controlled trial.

  1989cited by this paper
• Protein kinase C agonists inhibit bile secretion independently of effects on the microcirculation in the isolated perfused rat liver

  1989cited by this paper
• Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?

  1987cited by this paper
• Bile acid metabolism in cirrhotic liver tissue--altered synthesis and impaired hepatic secretion.

  1987cited by this paper
• Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up

  1985cited by this paper
• Influence of Hydroxylation and Conjugation of Bile Salts on Their Membrane‐Damaging Properties‐Studies on Isolated Hepatocytes and Lipid Membrane Vesicles

  1984cited by this paper
• Bile acid metabolism in liver disease

  1983cited by this paper
• Altered bile acid metabolism in primary biliary cirrhosis

  1981cited by this paper
• Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

  1981cited by this paper
• Urinary excretion of beta-aminoisobutyric acid after administration of thymine and nitrogen mustard.

  1957cited by this paper

• Alleviating Effects of Ursodeoxycholic Acid in Children with Acute Hepatitis A Infection: A Randomized Clinical Trial

  2019cites this paper
• Liver Fibrosis: A Clinical Update

  2019cites this paper
• Evidence-based clinical practice guidelines for liver cirrhosis 2015

  2016cites this paper
• Ursodeoxycholic Acid in Treatment of Non-cholestatic Liver Diseases: A Systematic Review

  2016cites this paper
• Prevention of hepatocellular carcinoma: Focusing on antioxidant therapy.

  2015cites this paper
• Study of Hepatoprotective Effect of Silymarin and Ursodeoxycholic Acid in Chronic Hepatitis C Patients

  2014cites this paper
• Inflammation in background cirrhosis evokes malignant progression in HCC development from HCV-associated liver cirrhosis

  2013cites this paper
• Pathophysiology and Treatment of Hepatitis C

  2012cites this paper
• Severe inflammation in the background liver cirrhosis correlates with the development of poorly differentiated HCC in HCV-associated liver cirrhosis.

  2012cites this paper
• Anti-Inflammatory Drugs Reduce the Risk of Hepatocellular Carcinoma Development

  2011cites this paper
• A common polymorphism in the ABCB11 gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver disease.

  2010cites this paper
• Hepatocyte death: a clear and present danger.

  2010cites this paper
• High serum alanine aminotransferase levels for the first three successive years can predict very high incidence of hepatocellular carcinoma in patients with Child Stage A HCV-associated liver cirrhosis

  2009cites this paper
• The ursodeoxycholic acid for the treatment of HCV infections

  2008cites this paper
• Effect of ursodeoxycholic acid on liver iron stores and distribution in rats with normal or iron-supplemented diet.

  2008cites this paper
• Detektion von Varianten und Polymorphismen im Nicht-Strukturprotein 5A des Hepatitis C Virusgenoms, die mit einer gesteigerten Resistenz oder Sensitivität des Virus gegenüber einer antiviralen Therapie mit Peg Inerferon alfa-2a und Ribavirin assoziiert sind

  2007cites this paper
• Reduction therapy of alanine aminotransferase levels prevent HCC development in patients with HCV-associated cirrhosis.

  2006cites this paper
• Traitements complmentaires de lhpatite chronique virale C

  2006cites this paper
• Therapie cholestatischer Lebererkrankungen

  2006cites this paper
• [Complementary treatments of chronic viral hepatitis C].

  2006cites this paper
• Immunomodulating and anti-apoptotic action of ursodeoxycholic acid: where are we and where should we go?

  2005cites this paper
• Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.

  2005influential citation
• Hydrophilic bile salt ursodeoxycholic acid protects myocardium against reperfusion injury in a PI3K/Akt dependent pathway.

  2005cites this paper
• Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection.

  2005cites this paper
• Sustained Low Alanine Aminotransferase Levels Can Predict the Survival for 10 Years without Hepatocellular Carcinoma Development in Patients with Hepatitis C Virus-Associated Liver Cirrhosis of Child Stage A

  2004cites this paper
• Serum alanine aminotransferase levels and survival after hepatectomy in patients with hepatocellular carcinoma and hepatitis C virus‐associated liver cirrhosis

  2003cites this paper
• Effects of ursodeoxycholic acid (ursodiol) treatment on chronic viral hepatitis in heart transplant patients: results of a prospective, double-blind, placebo-randomized study

  2003cites this paper
• Therapie cholestatischer Lebererkrankungen

  2002cites this paper
• Clinical Aspects of the Different Forms of Viral Hepatitis and Their Treatment

  2002cites this paper
• [Treatment of cholestatic liver diseases].

  2002cites this paper
• CHRONIC LIVER DISEASES: EPIDEMIOLOGY, PATHOPHYSIOLOGY, DIAGNOSIS AND TREATMENT Differences in the efficacy of ursodeoxycholic acid and bile acid metabolism between viral liver diseases and primary biliary cirrhosis

  2001cites this paper
• Use of ursodeoxycholic acid in liver diseases

  2001cites this paper
• Does the control of alanine aminotransferase levels lead to a regression of liver fibrosis in chronic hepatitis C patients?

  2001cites this paper
• Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.

  2001cites this paper
• Hepatitis C; a retrospective study, literature review, and naturopathic protocol.

  2000cites this paper
• Interferon and ursodeoxycholic acid combined therapy in chronic viral C hepatitis: controlled randomized trial in 203 patients.

  2000cites this paper
• Continuous Infusion of Cholecystokinin Leads to Down-Regulation of the Cholecystokinin-A Receptor in the Rat Pancreas

  2000cites this paper
• Randomized Trial of Interferon-Alpha plus Ursodeoxycholic Acid versus Interferon plus Placebo in Patients with Chronic Hepatitis C Resistant to Interferon

  2000cites this paper
• Ursodeoxycholic Acid Improves Liver Tests in Chronic Hepatitis

  1999cites this paper
• Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients.

  1999cites this paper
• Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease.

  1999cites this paper
• Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus‐associated cirrhosis

  1999cites this paper
• Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases

  1999cites this paper
• Effect of ursodeoxycholic acid in acute viral hepatitis.

  1999cites this paper
• Ursodeoxycholic acid in cholestasis: Potential mechanisms of action and therapeutic applications

  1998cites this paper
• Adjuvant treatment with ursodeoxycholic acid may reduce the incidence of acute cardiac allograft rejection.

  1998cites this paper
• Treatment of prolonged cholestasis of acute hepatitis B with ursodeoxycholic acid

  1998cites this paper
• Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis: a multicenter placebo-controlled study.

  1998cites this paper
• Tauroursodeoxycholic acid for the treatment of chronic hepatitis: a multicentre dose-response study

  1998cites this paper
• Therapy of Viral Hepatitis

  1998cites this paper
• The ursodeoxycholic acid for the treatment of HCV infections.

  1997cites this paper
• The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone.

  1997cites this paper
• Bile acid therapy in pediatric hepatobiliary disease: the role of ursodeoxycholic acid.

  1997cites this paper
• Long-Term Efficacy of Interferon-alpha and Ursodeoxycholic Acid in Treatment of Chronic Type C Hepatitis

  1997cites this paper
• [How should hepatitis C be treated? Treatment of chronic hepatitis C with therapeutic combinations].

  1997cites this paper
• Effect of Ursodeoxycholic Acid on Liver Tests in Chronic Hepatitis

  1997cites this paper
• Effect of ursodeoxycholic acid on HCV replication in subtyped chronic hepatitis C

  1996cites this paper
• Chronic administration of ursodeoxycholic and tauroursodeoxycholic acid changes microsomal membrane lipid content and fatty acid compositions in rats.

  1996cites this paper
• Effect of ursodeoxycholic acid on hypertransaminasaemia and bile acid composition in patients undergoing bone marrow transplantation--a double-blind randomized control study.

  1996cites this paper
• Efficacy of ursodeoxycholic acid in combination with interferon-alpha in treating chronic hepatitis C: results of a long-term follow-up trial.

  1996cites this paper
• Effect of tauroursodeoxycholic and ursodeoxycholic acid on ethanol-induced cell injuries in the human Hep G2 cell line.

  1995cites this paper
• Efficacy of ursodeoxycholic acid in the treatment of patients with chronic hepatitis C

  1995cites this paper
• The management of chronic hepatitis C virus infection.

  1995cites this paper
• [Viral hepatitis C].

  1995cites this paper
• Effect of ursodeoxycholic acid on biochemical parameters, hepatocyte proliferation and liver histology in galactosamine hepatitis in the rat

  1995cites this paper
• Effect of tauroursodeoxycholic acid on serum liver enzyme and serum lipid levels in patients with chronic active hepatitis

  1995cites this paper
• Interferon and ursodeoxycholic acid combined therapy in the treatmet of chronic viral C hepatitis: Results from a controlled randomized trial in 80 patients

  1995cites this paper
• Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis.

  1994cites this paper
• [Bile acids in therapy of liver diseases].

  1994cites this paper
• Gut Leading article The management of chronic hepatitis C virus infection

  year unknowncites this paper
• KEY FACTS Rational Pharmacologic Therapy of Hepatobiliary Disease in Dogs and Cats

  year unknowncites this paper